From Wikipedia, the free encyclopedia

Lactic acid/citric acid/potassium bitartrate
Combination of
Lactic acid Alpha hydroxy acid
Citric acid Tricarboxylic acid
Potassium bitartrate Sugar acid salt
Clinical data
Trade namesPhexxi
AHFS/ Drugs.com Multum Consumer Information
License data
Routes of
administration
Intravaginal
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Lactic acid/citric acid/potassium bitartrate, sold under the brand name Phexxi, is a non-hormonal combination medication used as a method of birth control. [1] [2] It contains lactic acid, citric acid, and potassium bitartrate. [1] [2] It is a gel inserted into the vagina. [2] [3]

The most common adverse reactions include vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain. [2]

Medical uses

The combination is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. [2]

History

The combination was approved for medical use in the United States in May 2020. [2] [4] [5]

References

  1. ^ a b c "Phexxi- lactic acid, l-, citric acid monohydrate, and potassium bitartrate gel". DailyMed. Retrieved 13 February 2022.
  2. ^ a b c d e f g "U.S. FDA Approves Evofem Biosciences' Phexxi (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy". Evofem Biosciences (Press release). 22 May 2020. Retrieved 22 May 2020 – via PR Newswire.
  3. ^ Steinberg J, Lynch SE (May 2021). "Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception". American Family Physician. 103 (10): 628–629. PMID  33982994.
  4. ^ "Phexxi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 23 May 2020.
  5. ^ "Drug Approval Package: Phexxi". U.S. Food and Drug Administration (FDA). 3 November 2020. Retrieved 13 February 2022.

External links